Brokerages Anticipate Kezar Life Sciences, Inc. (NASDAQ:KZR) Will Announce Earnings of -$0.31 Per Share

Wall Street brokerages predict that Kezar Life Sciences, Inc. (NASDAQ:KZRGet Rating) will report earnings per share (EPS) of ($0.31) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Kezar Life Sciences’ earnings, with the lowest EPS estimate coming in at ($0.34) and the highest estimate coming in at ($0.28). Kezar Life Sciences reported earnings per share of ($0.25) during the same quarter last year, which indicates a negative year over year growth rate of 24%. The business is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Kezar Life Sciences will report full year earnings of ($1.22) per share for the current financial year, with EPS estimates ranging from ($1.43) to ($1.07). For the next financial year, analysts expect that the company will report earnings of ($1.23) per share, with EPS estimates ranging from ($1.45) to ($0.99). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Kezar Life Sciences.

Kezar Life Sciences (NASDAQ:KZRGet Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02.

Several research analysts recently weighed in on KZR shares. Zacks Investment Research lowered Kezar Life Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, March 23rd. HC Wainwright upped their price target on Kezar Life Sciences from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, March 18th. Finally, Wells Fargo & Company dropped their price target on Kezar Life Sciences from $19.00 to $14.00 in a research report on Wednesday, May 4th.

In related news, Director Franklin M. Berger acquired 60,000 shares of the stock in a transaction dated Friday, March 18th. The shares were acquired at an average price of $16.74 per share, with a total value of $1,004,400.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Franklin M. Berger acquired 20,000 shares of the stock in a transaction dated Monday, March 21st. The shares were bought at an average cost of $14.77 per share, for a total transaction of $295,400.00. The disclosure for this purchase can be found here. Corporate insiders own 7.70% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of KZR. Metropolitan Life Insurance Co NY acquired a new position in shares of Kezar Life Sciences during the 1st quarter valued at about $89,000. Morgan Stanley increased its holdings in shares of Kezar Life Sciences by 12,201.9% during the 2nd quarter. Morgan Stanley now owns 1,580,546 shares of the company’s stock valued at $8,583,000 after acquiring an additional 1,567,698 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Kezar Life Sciences during the 3rd quarter valued at about $203,000. BlackRock Inc. increased its holdings in shares of Kezar Life Sciences by 1.2% during the 3rd quarter. BlackRock Inc. now owns 2,631,816 shares of the company’s stock valued at $22,739,000 after acquiring an additional 32,013 shares during the last quarter. Finally, Barclays PLC increased its holdings in shares of Kezar Life Sciences by 42.9% during the 3rd quarter. Barclays PLC now owns 31,999 shares of the company’s stock valued at $277,000 after acquiring an additional 9,614 shares during the last quarter. 71.03% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:KZR opened at $6.02 on Friday. Kezar Life Sciences has a 1-year low of $4.61 and a 1-year high of $18.55. The company has a debt-to-equity ratio of 0.04, a current ratio of 35.25 and a quick ratio of 35.25. The business’s fifty day moving average price is $13.50 and its 200 day moving average price is $13.35.

Kezar Life Sciences Company Profile (Get Rating)

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis.

Featured Stories

Get a free copy of the Zacks research report on Kezar Life Sciences (KZR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kezar Life Sciences (NASDAQ:KZR)

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.